Summary
Global Markets Direct’s, ‘Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2016’, provides an overview of the Severe Acute Respiratory Syndrome (SARS) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS)
- The report reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Severe Acute Respiratory Syndrome (SARS) therapeutics and enlists all their major and minor projects
- The report assesses Severe Acute Respiratory Syndrome (SARS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
CEL-SCI Corporation
GeneCure LLC
Inovio Pharmaceuticals, Inc.
Nanotherapeutics, Inc.
Novavax, Inc.
Phelix Therapeutics, LLC
Planet Biotechnology Inc.
Protein Sciences Corporation
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Severe Acute Respiratory Syndrome (SARS) Overview 8
Therapeutics Development 9
Pipeline Products for Severe Acute Respiratory Syndrome (SARS) - Overview 9
Pipeline Products for Severe Acute Respiratory Syndrome (SARS) - Comparative Analysis 10
Severe Acute Respiratory Syndrome (SARS) - Therapeutics under Development by Companies 11
Severe Acute Respiratory Syndrome (SARS) - Therapeutics under Investigation by Universities/Institutes 12
Severe Acute Respiratory Syndrome (SARS) - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Severe Acute Respiratory Syndrome (SARS) - Products under Development by Companies 15
Severe Acute Respiratory Syndrome (SARS) - Products under Investigation by Universities/Institutes 16
Severe Acute Respiratory Syndrome (SARS) - Companies Involved in Therapeutics Development 17
CEL-SCI Corporation 17
GeneCure LLC 18
Inovio Pharmaceuticals, Inc. 19
Nanotherapeutics, Inc. 20
Novavax, Inc. 21
Phelix Therapeutics, LLC 22
Planet Biotechnology Inc. 23
Protein Sciences Corporation 24
Severe Acute Respiratory Syndrome (SARS) - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 32
Drug Profiles 34
CEL-1000 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
D-3252 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
FDX-000 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Gene Therapy for Severe Acute Respiratory Syndrome - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
INO-4500 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Middle East respiratory syndrome coronavirus vaccine - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
ML-188 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Monoclonal Antibody for SARS Virus Infections - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
RBD-219N1 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
SARS (virus like particle) vaccine - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
severe acute respiratory syndrome vaccine - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
SSYA-10001 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Severe Acute Respiratory Syndrome (SARS) - Dormant Projects 50
Severe Acute Respiratory Syndrome (SARS) - Discontinued Products 53
Severe Acute Respiratory Syndrome (SARS) - Product Development Milestones 54
Featured News & Press Releases 54
Oct 19, 2015: Inovio and Partner Advance MERS Vaccine 54
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56
List of Tables
Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2016 9
Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Severe Acute Respiratory Syndrome (SARS) - Pipeline by CEL-SCI Corporation, H2 2016 17
Severe Acute Respiratory Syndrome (SARS) - Pipeline by GeneCure LLC, H2 2016 18
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 19
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Nanotherapeutics, Inc., H2 2016 20
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Novavax, Inc., H2 2016 21
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Phelix Therapeutics, LLC, H2 2016 22
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Planet Biotechnology Inc., H2 2016 23
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Protein Sciences Corporation, H2 2016 24
Assessment by Monotherapy Products, H2 2016 25
Assessment by Combination Products, H2 2016 26
Number of Products by Stage and Target, H2 2016 28
Number of Products by Stage and Mechanism of Action, H2 2016 30
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 33
Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, H2 2016 50
Severe Acute Respiratory Syndrome (SARS) - Dormant Projects (Contd..1), H2 2016 51
Severe Acute Respiratory Syndrome (SARS) - Dormant Projects (Contd..2), H2 2016 52
Severe Acute Respiratory Syndrome (SARS) - Discontinued Products, H2 2016 53
List of Figures
Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2016 9
Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 14
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Targets, H2 2016 27
Number of Products by Stage and Targets, H2 2016 27
Number of Products by Mechanism of Actions, H2 2016 29
Number of Products by Stage and Mechanism of Actions, H2 2016 29
Number of Products by Stage and Routes of Administration, H2 2016 31
Number of Products by Molecule Types, H2 2016 32
Number of Products by Stage and Molecule Types, H2 2016 32
